Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?

JOURNAL OF HEPATOLOGY

卷:55

Article

Piano, Salvatore¹  Morando, Filippo¹  Fasolato, Silvano¹  Cavallin, Marta¹  Boscato, Novella¹  Boccagni, Patrizia²  Zanus, Giacomo²  Cillo, Umberto²  Gatta, Angelo¹  Angeli, Paolo¹ 

[1] Univ Padua, Dept Clin & Expt Med, I-35100 Padua, Italy

[2] Univ Padua, Dept Gastroenterol & Surg, I-35100 Padua, Italy

关键词: Cirrhosis;    Portal hypertension;    Ascites;    Renal failure;    Bacterial infection;    Hepatorenal syndrome;    Vasoconstrictor;    Terlipressin;    Albumin;    MELD;    Liver transplantation;   

DOI  :  10.1016/j.jhep.2011.02.002

来源: Elsevier

【 摘 要 】

Background & Aims: The recurrence of type 1 hepatorenal syndrome has been described in up to 20% of responders to terlipressin and albumin after the discontinuation of the treatment. Subsequent recurrence of type 1 hepatorenal syndrome may require long-term treatment with terlipressin and albumin. Methods: We describe our experience of long-term administration of terlipressin as a bridge to LT in three patients with cirrhosis and recurrent type 1 hepatorenal syndrome. For all three patients we requested an early transplant which is an option recognized in our country to reduce waiting times for liver transplantation. Results: All three patients were transplanted within 2 months of onset of hepatorenal syndrome. All patients are still alive and none of them have developed chronic kidney disease. Conclusions: The outcomes of these patients suggest that long-term treatment with terlipressin and albumin is effective and well tolerated in patients with continuous recurrence of type 1 hepatorenal syndrome and, therefore, should be considered an absolute priority criterion in the allocation system for liver transplantation. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free